摘要
目的 探讨IMRT联合S-1对进展期食管癌患者的疗效及NLR、PLR等相关指标及预后的影响。方法 抽选局部晚期食管癌患者79例,随机分为研究组、对照组,其中研究组39例,采用IMRTl联合S-1治疗和对照组40例,采用常规放疗联合S-1治疗,比较2组患者的临床疗效等。结果 治疗3个月,研究组的疾病控制率(94.9%)显著高于对照组(80.0%)(P<0.05);治疗后研究组不良反应发生率(12.8%)显著低于对照组(35.0%)(P<0.05);治疗后研究组相关血清指标均较对照组改善明显(P<0.05);治疗后研究组患者的KPS评分较对照组改善明显(P<0.05)。结论 IMRTl联合S-1治疗局部晚期食管癌疗效更加显著,且不良反应较轻,同时可明显改善患者预后,值得临床推广应用。
Objective To investigate the analysis of clinical efficacy,inflammatory related indexes and prognosis of application of intensity-modulated radiotherapy combined with S-1 in the treatment of patients with locally advanced esophageal cancer.Methods To screening 61 cases of patients with locally advanced esophageal cancer as research subjects,it will be divided into the study group with 31 cases and the control group with 30 cases,patients in the control group were treated with routine radiotherapy with S-1 and patients in the study group were treated with IMRTl with S-1 therapy,then the 2 groups were compared in terms of clinical efficacy and so on.Results The clinical efficacy in the study group was higher than the control group after treatment(P<0.05);The side reaction rates in study group were lower than the control group after treatment(P<0.05);The inflammatory related indexes in study group were better than the control group after treatment(P<0.05);The prognosis in the study group was better than the control group after treatment(P<0.05).Conclusion The intensity-modulated radiotherapy combined with S-1 in the treatment of patients with locally advanced esophageal cancer is more significant,it is worthy of popularization and application.
作者
吕晶晶
邹明雷
付培彪
LV Jingjing;ZOU Minglei;FU Peibiao(Second People’s Hospital of Jiaozuo,Jiaozuo,454150)
出处
《实用癌症杂志》
2022年第6期933-935,979,共4页
The Practical Journal of Cancer
基金
2019年度河南省医学科技攻关计划联合共建项目(编号:LHGJ20190027)。
